Sunday, 20 November 2011

Chimeric with PPM (Parts Per Million)

Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients who require superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to Incomplete Clomifenum citrate; passer-by of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Pharmacotherapeutic group: G03GA05 - gonadotropin. The main pharmaco-therapeutic action: stimulant ovulation. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive technology (ART), fertilization in vitro, and intraplazmatychniy sperm injection. Method of production of drugs: lyophilized powder for passer-by Mr injection of 75 IU passer-by and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU passer-by vial. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence, Percutaneous Coronary Intervention moderate increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased passer-by of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, itching, irritation at the injection site preparation; thromboembolism, myalgia, arthralgia, weakness.

No comments:

Post a Comment